Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067105 · ClinicalTrials.gov registry record · Phase 3
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 824
- Enrollment target
NCT01067105 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 824 participants.
The verdict
NCT01067105, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 824 participants
- Enrollment target
Study Summary
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.
Interventions
- DRUG ciclesonide HFA 160 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 824 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067105
The ClinicalTrials.gov registry entry for NCT01067105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 824 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ciclesonide HFA 160 μg is the first listed.
NCT01067105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067105 about?
NCT01067105 is a clinical study titled "A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older". 6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.
What is the current status of trial NCT01067105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 824 participants. The study started on 2010-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01067105?
The interventions under investigation include: ciclesonide HFA 160 μg (DRUG).
Who is sponsoring clinical trial NCT01067105?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.